Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with high morbidity. The Quality of Life (QoL) assessment in this patient group with a limited life expectancy and high recurrence rate is important. Published data show an impairment of postoperative Quality of Life at 3 months postoperatively with an improvement over 6-12 months at levels higher than the baseline. Standardized instruments QoL have to be included in clinical trials assessing the efficacy of CRS and HIPEC.
Piso
Pompiliu
P
University Medical Center Regensburg, Regensburg, Germany. pompiliu.piso@klinik.uni-regensburg.de
Glockzin
Gabriel
G
von Breitenbuch
Phillipp
P
Popp
Felix Cristoph
FC
Dahlke
Marc Hendrik
MH
Schlitt
Hans J
HJ
Nissan
Aviram
A
D010478:Chemotherapy, Cancer, Regional Perfusion; D003131:Combined Modality Therapy; D006801:Humans; D006979:Hyperthermia, Induced; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery*; D011788:Quality of Life